Related Experiment Video
Updated: Apr 29, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Advances in the treatment of non-small cell lung cancer
1Presented by Leora Horn, MD, MSc, Associate Professor of Medicine, Department of Hematology Oncology; Clinical Director, Thoracic Oncology Research Program, Vanderbilt University, Nashville, Tennessee.
Abstract:
Clinical trial data continue to emerge on treatments in advanced non-small cell lung cancer (NSCLC), supporting the strategy that histology and molecular driver mutations should guide treatment selection. During her presentation at the NCCN 19th Annual Conference, Dr. Leora Horn highlighted 3 specific areas in which the 2014 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for NSCLC focus attention: updates on the assortment of chemotherapy options, targeted therapies and how acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors appears to have become the catalyst of the development of newer-generations of agents, and the revisited role of newer immunotherapeutic options.
Insights
Treatment for advanced non-small cell lung cancer (NSCLC) should be guided by tumor histology and molecular mutations. Recent guidelines emphasize chemotherapy, targeted therapies addressing resistance, and emerging immunotherapies for NSCLC.
Area of Science:
- Oncology
- Cancer Research
- Clinical Practice Guidelines
Background:
- Evolving clinical trial data in advanced non-small cell lung cancer (NSCLC) reinforce personalized treatment strategies.
- Histology and molecular driver mutations are critical factors in selecting optimal therapies for NSCLC patients.
Discussion:
- Updates to the 2014 NCCN Clinical Practice Guidelines for NSCLC address chemotherapy, targeted therapies, and immunotherapies.
- Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors drives the development of next-generation targeted agents.
- The role of novel immunotherapeutic options in NSCLC treatment is being re-evaluated.
Key Insights:
- Personalized medicine based on molecular profiling is paramount in advanced NSCLC.
- Understanding and overcoming acquired resistance is key to advancing targeted therapy efficacy.
- Immunotherapy represents a significant and expanding frontier in NSCLC treatment.
Outlook:
- Continued research into resistance mechanisms will likely yield more effective targeted therapies.
- Further investigation into the synergistic potential of combined immunotherapies and targeted agents is warranted.
- The integration of genomic data into clinical decision-making will continue to refine NSCLC treatment paradigms.
More Related Videos
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...